Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuevolution, Merck License Agreement

Published: Friday, February 21, 2014
Last Updated: Friday, February 21, 2014
Bookmark and Share
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.

Under terms of the agreement, Merck will gain exclusive rights for the further development and commercialization of the compounds. This is the second agreement between Nuevolution and Merck. Nuevolution will receive an undisclosed upfront payment and milestone payments for certain preclinical, clinical and agreed upon commercial milestones.  In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.  Further financial details were not disclosed.

With this agreement, Nuevolution delivers on its new strategy to transform from a technology platform biotech company to a lead compound development company, providing novel products to improve future health treatments for patients.

Nuevolution applies its Chemetics® platform to identify small molecule drug candidates for therapeutically important targets. Chemetics® uses proprietary innovative DNA labelling to allow small molecule screening at an unprecedented scale for lead discovery. The technology allows efficient screening of billions of molecules against biological targets. Nuevolution has patented its Chemetics® technology and holds a strong validated patent portfolio within the technology field. In its existing collaborations and internal pipeline development, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.

“This agreement is the first pre-clinical compound out-licensing agreement for Nuevolution. It marks the immediate realization of our chosen strategy to both offer access to our technology as well as out-license leads identified by the use of the Chemetics® platform” said Alex Gouliaev, CEO of Nuevolution A/S and continued, “We are very pleased to see that the compounds will be developed further by Merck.”

Stig Løkke Pedersen, Chairman of Nuevolution A/S adds: “looking at our deal track record, Chemetics® has provided us with a commercially proven lead discovery engine. The out-licensing of compounds represents the best future source of sustainable growth for the company. It is very encouraging to see existing partnerships develop into long term relationships.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuevolution A/S Appoints Professor Mark C. Genovese as Advisor
Appointment to support the companies’ pre-clinical and clinical efforts in inflammatory diseases.
Saturday, November 21, 2015
Nuevolution Announces Drug Discovery Collaboration with J&J Innovation
Company will apply its drug discovery platform Chemetics® to discover and advance drug candidates.
Tuesday, October 27, 2015
Dr. Jeanette Wood Joins Nuevolution
Jeanette joins the Company as director and senior scientific advisor to the board of directors.
Tuesday, September 22, 2015
Nuevolution Appoints Henrik Simonsen
Former Director of Life Science Corporate Finance at SEB joins as its Chief Financial Officer.
Thursday, September 17, 2015
Professor Paul Workman Joins Nuevolution as Scientific Advisor
Professor Workman brings a vast knowledge and expertise within the oncology field.
Friday, July 11, 2014
Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution Announces Technology Licensing Agreement
Agreement with Novartis for use of Nuevolution’s Chemetics® technology.
Friday, January 10, 2014
Nuevolution Appoints Ton Berkien as Chief Business Officer
Ton Berkien will join the company on January 1, 2014.
Tuesday, December 10, 2013
Nuevolution Announces Formation of Strong Scientific Advisory Panel
Company teams with scientific advisors to assist the progression of its internal drug discovery programs.
Thursday, March 14, 2013
Nuevolution A/S Raises € 11 Million in New Financing Round
New financing round will enable Nuevolution to transform its current business model.
Friday, June 22, 2012
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
Breaking Cell Barriers with Retractable Protein Nanoneedles
Adapting a bacterial structure, institute researchers have developed protein actuators that can mechanically puncture cells.
Gene Signature could Lead to a New Way of Diagnosing Lyme Disease
Lyme disease patients had distinctive gene signatures that persisted for at least three weeks, even after they had taken the antibiotics.
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
NIH Seeks Research Applications to Study Zika in Pregnancy, Developing Fetus
Institute has announced that the new effort seeks to understand virus effect on reproduction and child development.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!